MAEM Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable

The MAEM Pharma Grade API, identified by the designation MAEM, is a controlled-crystalline active pharmaceutical ingredient released under a route-differentiated specification family for solid oral dosage forms and sterile injectable manufacturing. The oral grade is supplied after nitrogen air-jet milling at 0.60–0.80 MPa to a particle-size envelope of D90 15–60 µm; the injectable grade is micronized to D90 5–20 µm and controlled to a residual moisture ceiling of 0.30% w/w by Karl Fischer titration, compared with 0.50% w/w for oral release. Both grades are tested for loss on drying at 105°C to constant weight and must satisfy the residual solvent limits defined in Ph. Eur. 5.4 and USP 467. Elemental impurity risk is assessed using ICH Q3D Option 6 concentration limits, with separate oral and injectable assessments updated at intake of each starting material. The designation MAEM does not refer to a single powder; it identifies a specification platform with separate packaging, microbiological, and particle characterisation protocols for tablet, capsule, granule, oral, and injectable applications.

What Inhibits Direct Substitution of Oral Grade into Injectable Manufacturing?

Route conversion from oral-grade MAEM to injectable-grade MAEM is not achieved by terminal sterilization alone. The injectable grade is specified for aseptic processing or terminal sterilization and carries a bacterial endotoxin release limit of 0.25 EU/mg for parenteral dosing, with lot release performed according to Ph. Eur. 2.6.14 and USP 85. Subvisible particulate matter is evaluated by light obscuration under USP 788 Method 1; release requires not more than 600 particles/container at ≥10 µm and not more than 60 particles/container at ≥25 µm. Bioburden in the injectable path is monitored under 21 CFR 211.113, with pre-filtration bioburden commonly not exceeding 10 CFU/100 mL. Oral-grade MAEM may retain higher surface moisture and particle fines that are acceptable for tablet dissolution and capsule disintegration but can alter sedimentation volume, flocculation, and wetting behaviour in an injectable suspension. The injectable grade should be opened only in Grade C or ISO 7 controlled areas; subdivided powder should not be returned to stock after opening.

In direct compression, MAEM oral grade with a bulk density of 0.45–0.65 g/mL and Carr index 15–25 is blended in a bin blender for 10–20 min at 8–12 rpm. Magnesium stearate is added as the final lubricant at 0.5–1.0 wt% for 3 min; lubricant fractions above 1.5 wt% reduce tablet hardness and can delay dissolution below the USP 711 Q value at 15 min and 30 min. Tablet compaction on a rotary press at 10–25 kN main compression force and 5–10 kN pre-compression typically yields tensile strength in the range of 1.5–2.5 MPa when the formulation contains 1.0–2.5 wt% copovidone or 25–50 wt% microcrystalline cellulose. Wet granulation uses a high-shear granulator at 300–500 rpm impeller speed and 1500–2500 rpm chopper speed; purified water or 5–10% w/w povidone binder solution is added over 3–5 min. The wet mass is passed through a 1.0–2.0 mm screen and dried in a fluid-bed dryer with inlet air at 50–65°C until loss on drying reaches 1.0–2.0%. Dried granule D50 is targeted at 100–250 µm, and capsule filling on a dosator machine is adjusted to fill weight variation not exceeding ±5.0%.

Solubility, Polymorph, and Particle-Size Constraints in a Dual-Route API

Polymorphic identity is controlled by X-ray powder diffraction, with the undesired polymorph limited to not more than 5.0 area% in both grades. Solubility is measured by the shake-flask method in phosphate buffer at pH 6.8 and 37±0.5°C. Oral-grade material with larger particles may reach equilibrium at 80–120 mg/mL after 24 h, while the micronized injectable grade may reach equilibrium within 4–6 h under stirring at 300 rpm. If solubility in Water for Injection is below 20 mg/mL, the injectable formulation may require pH adjustment to 4.5–7.0 or a cosolvent system containing PEG 300 or propylene glycol at 10–30% v/v. Final injectable osmolality is adjusted with sodium chloride or dextrose to 270–320 mOsm/kg under Ph. Eur. 2.2.35. The oral grade is not optimised to the same sub-5 µm fines distribution because excessive micronisation creates triboelectric charging and segregation during tableting; conversely, injectable-grade particles may be too fine for reliable dosator filling without flow aids or granulation.

For lyophilised presentations, MAEM injectable grade is dissolved at 20–50 mg/mL in Water for Injection and filtered through a 0.22 µm PVDF membrane. The solution is filled into Type I borosilicate vials and placed onto a shelf lyophiliser. Freezing is conducted at -40°C for 4–6 h. Primary drying is performed at shelf temperature -20°C under chamber pressure 80–150 mTorr for 30–40 h; secondary drying at 30°C for 6–8 h targets residual water below 1.0% by Karl Fischer. Reconstitution time is assessed by adding 5 mL of Water for Injection and should be below 2 min. After capping, the cake should not be exposed to relative humidity above 60% RH; moisture uptake above 2.0% w/w can reduce glass transition temperature and induce cake collapse. Published data for MAEM-specific lyophilisation collapse temperature is limited, so differential scanning calorimetry on the frozen formulation is required before scale-up.

When the MAEM Injectable Grade Is Exposed to Terminal Sterilization

If terminal moist-heat sterilization is selected, the injectable solution should be autoclaved at 121–124°C for 15–20 min only after stability data confirm that assay loss remains below 2.0% and total degradation products remain below 0.5% from initial. Terminal sterilization is not recommended if the MAEM solution contains more than 5.0% ethanol or if pH is below 3.5 because hydrolysis risk increases. Filter integrity is checked by bubble point or diffusive flow before and after filling, with post-use bubble point not lower than the manufacture-defined minimum for the 0.22 µm membrane. Maximum holding time between dissolution and sterile filtration is 4 h at 20–25°C. Rotary stoppering and capping are followed by container closure integrity testing under USP 1207 using dye immersion or vacuum decay, with rejection not exceeding 0.2% in routine production. Headspace oxygen should remain below 2.0% if the API is oxygen-sensitive. Contact with non-siliconised or poorly washed rubber stoppers should be avoided because stopper particles can elevate subvisible particulate counts in the finished injectable product.

Compared with conventional single-route API grades, the MAEM Pharma Grade is not a single powder with one particle size and one microbial specification. Single-route oral APIs are typically released only with total aerobic microbial count and residual solvent limits, while single-route injectable APIs may be over-micronised and packaged sterile, which can impair flow and make direct compression difficult without re-granulation. The MAEM specification platform therefore separates oral and injectable grades. The oral grade is packaged in double low-density polyethylene bags inside a fibre drum and is released with total aerobic microbial count not exceeding 1000 CFU/g, total yeast and mold count not exceeding 100 CFU/g, and absence of Escherichia coli per 10 g as described in Ph. Eur. 5.1.4. The injectable grade is packaged in single-use sterile bags inside a gamma-irradiated outer container and is released with sterility under USP 71 and Ph. Eur. 2.6.1, endotoxin under Ph. Eur. 2.6.14 and USP 85, particulate matter under USP 788, and container closure integrity under USP 1207. Separate batch records are maintained for each grade; reclassification from oral to injectable is not permitted because the oral path lacks the controlled aseptic and endotoxin-management chain.

Stability chambers for the oral grade are set at 25°C/60% RH and 40°C/75% RH; the injectable grade is stored in inverted vial orientation at the same conditions for up to 6 months accelerated and 24–36 months long-term. Assay and impurities are measured by HPLC with UV detection, and mass balance is required to be 97.0–103.0%. Photostability studies under ICH Q1B may indicate the need for amber glass protection above 10 kLux·h cumulative visible light and 200 Wh/m² near-UV energy. Homogeneity of the API in capsule blends is tested by stratified sampling from the blender at 10 locations; acceptance is 90.0–110.0% of target assay with relative standard deviation not more than 5.0%. Twin-screw granulation, if required for taste-masking or modified release, should use mixing elements with L/D ratio 25:1 and barrel temperature set 10–15°C below melting onset to prevent amorphous conversion.

MAEM oral grade should be stored at 15–25°C and not more than 60% RH. If opened above 60% RH, pre-drying in a vacuum oven at 40°C for 4–6 h is required before tableting. The API should not be dry-blended with strong oxidising agents; forced degradation with 0.3% hydrogen peroxide under ICH Q1A is used to detect oxidation-sensitive impurities. Injectable-grade material should not remain in silicone tubing beyond 2 h because extractables may raise total organic carbon above 500 ppb in the final container. Oral-grade MAEM may be micronised only under nitrogen; dry air milling above 80% RH can alter polymorph content and increase moisture. These constraints define routine processing boundaries rather than product failure criteria.